
Why Primary Care Is Key to Catching CKM Syndrome Early
Early CKM syndrome screening in primary care, from A1c and UACR to lipids and PREVENT risk scores, offers the best chance to prevent progression.
Early identification of
“In practice, our patients are complicated. They don’t often have just one thing,” DiPalo told Patient Care Online.
Why Did CKM Need Its Own Framework?
In 2023, the American Heart Association (AHA) established the term “CKM syndrome” to recognize the complex interrelatedness among heart disease, kidney disease, obesity, and diabetes.1 The burden is substantial: almost 90% of U.S. adults met criteria for CKM syndrome (stage 1 or higher) and 15% met criteria for advanced stages.2 DiPalo notes that separate cardiology, nephrology, and diabetes guidelines had led to siloed care and, at times, conflicting recommendations, which a unified framework helps resolve.
What Should Routine CKM Assessment Include?
DiPalo recommends screening hemoglobin A1c for diabetes, estimated glomerular filtration rate and urine albumin-creatinine ratio for kidney disease, and blood pressure, body mass index, and waist circumference at every visit. Lipid testing is also central. The 2026 ACC/AHA multisociety dyslipidemia guideline strongly supports dyslipidemia measurement and management through the lifetime, promoting universal lipid testing, and recommends use of the newer PREVENT-ASCVD equations instead of the older Pooled Cohort Equations for 10- and 30-year risk assessment. If LDL-C levels are not adequately lowered by healthy lifestyle habits and statin therapy, which remains the foundation of lipid-lowering and risk reduction, the guideline recommends the addition of non-statin therapies.3
She adds that many diabetes therapies were later found to protect the heart and kidneys, allowing clinicians to choose treatments that address multiple CKM pathways at once.
Watch part 1 of the interview to hear DiPalo explain how the PREVENT calculator can guide lipid-lowering decisions, when to escalate therapy, and why early kidney screening matters for delaying disease progression.
References
- Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184
- Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020. JAMA. 2024;331(21):1858-1860. doi:10.1001/jama.2024.6892
- ACC/AHA issue updated guideline for managing lipids, cholesterol. American College of Cardiology. March 13, 2026. Accessed November 19, 2026.
https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol
Related to this article








